Journal: Frontiers in Immunology

Article Title: Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose

doi: 10.3389/fimmu.2023.1123158

Figure Lengend Snippet: Analysis of B cell frequency in infection-naïve and previously infected vaccine recipients over time. (A) Representative flow cytometry pseudocolor plots of spike-specific B cells in pre-pandemic healthy donor (HD), in an infection-naïve and a previously infected subject. (B, C) Percentages of tetramer + on CD19 + B cells (B) and the percentages of memory CD27 + , IgG + CD27 + and IgA + CD27 + B cells on tetramer + B cells (C) are shown for the spike and RBD protein of the Wuhan Hu-1 SARS-CoV-2 and in response to the B.1.1.529.1 (Omicron) spike protein in infection-naïve and previously infected subjects at 9 months after primary vaccination (T3) and 3 months after the booster dose (T4), as well as for pre-pandemic HD. * p-value <0.05 vs infection-naïve and previously infected subjects at T3 and T4; # p-value <0.05 vs infection-naïve subjects at T3. The sample size ( n ) for all B cell analyses is indicated in brackets in panel (B) .

Article Snippet: Live singlets were gated based on 7AAD fluorescence and specific B cells detected using the double discrimination method gated on CD3 - CD14 - 7AAD - and CD19 + cells (CD3 PerCP-Vio700, #130-113-132; CD14 PerCP-Vio700, #130-113-151, Miltenyi).

Techniques: Infection, Flow Cytometry

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: The use of peripheral CD3 + γδ + Vδ2 + T lymphocyte cells in combination with the ALBI score to predict immunotherapy response in patients with advanced hepatocellular carcinoma: a retrospective study

doi: 10.1007/s00432-024-05896-y

Figure Lengend Snippet: Peripheral lymphocyte subsets in patients with advanced HCC.

Article Snippet: For intracellular cytokine expression, cells were stimulated with phorbol myristate acetate (PMA, Sigma-Aldrich, Germany) and brefeldin A (BFA, BD Biosciences, USA) at 37 oC for 5 h. The following monoclonal antibodies were used: APC-H7 Mouse Anti-Human CD3 (BD Bioscience, USA); BV605 Mouse Anti-Human CD4 (BD Bioscience, USA); FITC Mouse Anti-Mouse CD8 (BD Bioscience, USA); BV421 Mouse Anti-Human γδ TCR (BD Bioscience, USA); PE Mouse Anti-Human CD279 (BD Bioscience, USA); APC Anti-Human CD366 (Tim-3, BioLegend, USA); Brilliant Violet 510 Anti-Human TCR Vδ2 (BioLegend, USA); PerCP-Vio 700 Anti-Human TCR Vδ1 (Miltenyi Biotec, Germany); and PE-Cy7 Mouse Anti-Human CD28 (BD Bioscience, USA).

Techniques: